DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Gossypol is an investigational drug.
There have been 10 clinical trials for Gossypol. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are National Cancer Institute (NCI), Mayo Clinic, and Third Military Medical University.
There are seven hundred and fifty-eight US patents protecting this investigational drug and four international patents.
Recent Clinical Trials for Gossypol
|R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma||National Cancer Institute (NCI)||Phase 1/Phase 2|
|R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma||Mayo Clinic||Phase 1/Phase 2|
|Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Phase 1/Phase 2|
Top disease conditions for Gossypol
Top clinical trial sponsors for Gossypol
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Gossypol||See Pricing||Heterocyclic compounds useful in the treatment of disease||Epigen Biosciences, Inc. (San Diego, CA)||See Pricing|
|Gossypol||See Pricing||Pyrazol-3-ones that activate pro-apoptotic BAX||Dana-Farber Cancer Institute, Inc. (Boston, MA)||See Pricing|
|Gossypol||See Pricing||Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders||Dana-Farber Cancer Institute, Inc. (Boston, MA)||See Pricing|
|Gossypol||See Pricing||Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor||The Regents of the University of California (Oakland, CA)||See Pricing|
|Gossypol||See Pricing||Methods and compositions for treating infection||UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS)||See Pricing|
|Gossypol||See Pricing||Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy||University of Georgia Research Foundation Inc. (Athens, GA)||See Pricing|
|Gossypol||See Pricing||Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids at the sn-2 position||COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (Acton, AU) GRAINS RESEARCH AND DEVELOPMENT CORPORATION (Barton, AU) NUSEED PTY LTD. (Laverton North, AU)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Gossypol||Eurasian Patent Organization||201591607||2033-03-15||See Pricing|
|Gossypol||European Patent Office||2988743||2033-03-15||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|